Cantel Medical Corp. (NYSE:CMN) shares hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $75.00 and last traded at $74.46, with a volume of 198,946 shares traded. The stock had previously closed at $72.03.

Several research analysts have recently issued reports on the company. Needham & Company LLC assumed coverage on Cantel Medical Corp. in a research report on Wednesday, August 24th. They issued a “hold” rating for the company. Benchmark Co. assumed coverage on Cantel Medical Corp. in a research report on Monday. They issued a “buy” rating and a $83.00 target price for the company.

The firm has a 50 day moving average of $69.36 and a 200-day moving average of $68.17. The company has a market cap of $3.09 billion and a P/E ratio of 54.67.

Cantel Medical Corp. (NYSE:CMN) last posted its quarterly earnings results on Wednesday, June 8th. The company reported $0.44 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.36 by $0.08. The company had revenue of $173.70 million for the quarter, compared to the consensus estimate of $163.16 million. The business’s revenue was up 22.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.35 EPS. Analysts forecast that Cantel Medical Corp. will post $1.43 earnings per share for the current fiscal year.

In related news, Director Mark N. Diker sold 7,000 shares of the business’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $73.30, for a total value of $513,100.00. Following the completion of the transaction, the director now owns 439,872 shares of the company’s stock, valued at $32,242,617.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Jorgen B. Hansen sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 15th. The stock was sold at an average price of $72.44, for a total transaction of $144,880.00. Following the completion of the transaction, the chief operating officer now directly owns 41,383 shares of the company’s stock, valued at approximately $2,997,784.52. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Cantel Medical Corp. stock. Principal Financial Group Inc. raised its position in Cantel Medical Corp. (NYSE:CMN) by 4.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 242,720 shares of the company’s stock after buying an additional 10,052 shares during the period. Principal Financial Group Inc. owned about 0.59% of Cantel Medical Corp. worth $15,082,000 as of its most recent SEC filing.

Cantel Medical Corp. is a provider of infection prevention and control products and services in the healthcare market. The Company’s segments include Endoscopy, Water Purification and Filtration, Healthcare Disposables, Dialysis and Specialty Packaging. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.